NCT00141479已完成2 期
A Single-center Safety and Tolerability Study to Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to investigate a safe treatment interruption interval(s) for re-initiation of bifeprunox at a therapeutic dose. The study duration is approximately 7 to 10 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of Schizophrenia or Schizoaffective disorder
- •18-55 years
排除标准
- •Subjects who are acutely psychotic
- •Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia
- •Subjects at significant risk of suicide
- •Subjects with a seizure disorder
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck CancersHead and Neck CancersCervical CancerAnal CancerNCT05122221Corregene Biotechnology Co., Ltd12
招募中
1 期
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid TumorHead and Neck Squamous Cell CarcinomaVagina TumorCarcinoma of PenisAnal CarcinomaCarcinoma of VulvaCervical CancerOropharyngeal CancerNCT05787535HRYZ Biotech Co.17
已完成
1 期
Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)Benign Prostatic HyperplasiaNCT01454349Sophiris Bio Corp40
招募中
1 期
Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.Systemic Lupus ErythematosusNCT06657703HC Biopharma Inc.38
已完成
1 期
Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy SubjectsChronic HBV InfectionNCT05851261Zhejiang Palo Alto Pharmaceuticals, Inc.60